Mekonos raises $4.6M for its gene engineering platform

This post was originally published on this site

<p xmlns="https://www.w3.org/1999/xhtml"><span class="xn-location">SAN FRANCISCO, <span class="xn-chron">Nov. 23, 2020 /PRNewswire/ – Mekonos, a biotech company <b>launching the first-of-its kind system-on-a-chip (SoC) for targeted ex vivo gene engineering</b>, today announced it has completed a <span class="xn-money">$4.6 million financing round.

Bastion Balance Seoul, Korea.